INTERNATIONAL JOURNAL OF
PHARMACEUTICAL AND HEALTHCARE INNOVATION
journal homepage: www.ijphi.com

Review Article

OPEN ACCESS

A Comprehensive Clinical Review on Precision Medicine in Cardiovascular Diseases

Sandra Marry Cherian[1], Ramdas Bhat[2]

[1]PG scholar, Department of Pharmacy Practice, Srinivas College of Pharmacy, Valachil, Farangipete Post, Mangalore, Karnataka, India. 574143

[2]Associate Professor, Department of Pharmacology, Srinivas College of Pharmacy, Valachil, Farangipete Post, Mangalore, Karnataka, India. 574143

Article Info

Article history:

Manuscript ID:

IJPHI2222262024
Received: 22- June -2024
Revised :22-july-2024
Accepted: 26-August-2024
Available online: August 2024

Keywords:
precision medicine,

cardio vascular disease, genomics, biomarkers, artificial intelligence.

Corresponding Author:

ramdas21@gmail.com

Abstract

Cardiovascular diseases (CVD) continue to pose a significant global health challenge, contributing substantially to morbidity and mortality worldwide. Despite advances in medical science, the intricate interplay of genetic predispositions, environmental factors, and lifestyle choices complicates effective CVD management. Precision medicine offers a transformative approach by tailoring healthcare interventions to individual patient profiles, integrating data from genomics, proteomics, and digital health sources to enhance diagnostic accuracy, optimize treatment efficacy, and improve outcomes. However, the adoption of precision medicine in cardiovascular care faces formidable socio-political barriers, requiring robust digital infrastructure and collaborative efforts across stakeholders to overcome challenges related to data integration, privacy concerns, and ethical implications. This comprehensive review explores genetic insights in CVDs, omics technologies, risk prediction strategies, pharmacogenomics, targeted therapies, and the ethical considerations pivotal to advancing precision medicine in cardiovascular health. Future directions highlight the promise of genomics, biomarker discovery, and artificial intelligence in revolutionizing CVD management, emphasizing the potential for personalized, effective, and equitable healthcare solutions.

INTRODUCTION

Cardiovascular diseases (CVD) represent a persistent global health challenge, accounting for a substantial burden of mortality and morbidity across diverse populations [1]. Despite advancements in medical science, the complex interplay of genetic predispositions, environmental factors, and lifestyle choices complicates effective management and treatment of CVD [2]. Precision medicine emerges as a promising paradigm that tailors healthcare interventions to individual patient profiles, integrating data from various sources such as genomics, proteomics, and patient-generated health data. By harnessing these insights, precision medicine aims to enhance diagnostic accuracy, optimize treatment efficacy, and ultimately improve outcomes for individuals at risk or affected by CVD [3-5].

However, the adoption of precision medicine in cardiovascular care is not without challenges. Socio-political barriers, including healthcare policy and resource allocation, present formidable hurdles to widespread implementation [6]. Furthermore, the integration and analysis of vast datasets required for precision medicine approaches demand robust digital infrastructure and advanced analytics capabilities [7]. Overcoming these obstacles necessitates collaborative efforts among healthcare providers, researchers, policymakers, and technology developers to create an ecosystem supportive of personalized cardiovascular care [8].

This review aims to provide a comprehensive exploration of precision medicine's current landscape in cardiovascular diseases. It will examine key concepts, methodologies, and potential applications of precision medicine in CVD management. By synthesizing evidence from genetics, biomarker identification, targeted therapies, digital health innovations, and ethical considerations, this review seeks to offer a holistic understanding of the transformative potential of precision medicine in cardiovascular care.

GENETIC INSIGHTS IN CARDIOVASCULAR DISEASE

Genetic research in cardiovascular diseases (CVDs) has profoundly advanced our understanding of disease mechanisms and therapeutic opportunities. Researchers have identified key genes involved in lipid metabolism, such as the LDL receptor (LDLR), Apolipoprotein B (APOB), and Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9), whose mutations contribute to dyslipidemia and accelerate atherosclerosis and coronary artery disease progression [9, 10]. Additionally, studies on gene expression profiles in cardiovascular tissues have revealed dysregulated genes like Natriuretic Peptide Precursor A (NPPA) and Natriuretic Peptide Precursor B (NPPB), critical for cardiac function and implicated in CVD pathogenesis [11]. Genes influenced by epigenetic modifications, such as Endothelial Nitric Oxide Synthase (eNOS) and Angiotensin-Converting Enzyme (ACE), play pivotal roles in vascular function and blood pressure regulation [12]. Genome-wide association studies (GWAS) have identified genetic variants in loci like 9p21 (CDKN2B-AS1) and LPA, which correlate with increased risk of coronary artery disease and atherosclerosis, facilitating personalized risk assessment and treatment strategies [13]. Moreover, CRISPR-Cas9 gene editing technology offers promising avenues for precise modification of disease-associated genetic sequences, potentially revolutionizing therapeutic interventions in CVDs by correcting mutations or modulating gene expression [14].



Figure 1 Genetic Insights in CVDs

OMICS TECHNOLOGY IN CVD's

Genomics, transcriptomics, proteomics, metabolomics, and epigenomics have collectively transformed our understanding of cardiovascular diseases (CVDs) by delving deep into molecular mechanisms. Genomics, for instance, explores variations like SNPs and CNVs, identifying genes such as LDL receptor (LDLR) and Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) that influence dyslipidemia and atherosclerosis risk [15-18]. Transcriptomics focuses on RNA expression patterns, revealing insights into genes like Natriuretic Peptide Precursors (NPPA and NPPB) crucial for cardiac function and CVD pathogenesis [19,20]. Proteomics investigates protein profiles, highlighting molecules like Matrix

Metalloproteinase 9 (MMP9) and Tumor Necrosis Factor-alpha (TNF-alpha) involved in CVD inflammatory processes [21,22]. Metabolomics examines metabolic pathways, identifying biomarkers linked to CVD risk factors such as dyslipidemia and oxidative stress, offering targets for personalized treatments [23,24]. Epigenomics studies epigenetic modifications impacting genes like Endothelial Nitric Oxide Synthase (eNOS) and Angiotensin-Converting Enzyme (ACE), crucial for vascular function and blood pressure regulation, suggesting novel therapeutic avenues [25,26].



Figure 2 Omics technology in CVD's

RISK PREDICTION AND PREVENTION IN CVD's

Advances in genomic research have illuminated a spectrum of genetic variants associated with heightened cardiovascular disease (CVD) risk, spanning common single nucleotide polymorphisms (SNPs) to rare Mendelian disorders. These genetic markers provide crucial insights into an individual's predisposition to specific CVDs such as coronary artery disease (CAD), hypertension, and dyslipidemia. Genetic risk scores derived from genome-wide association studies (GWAS) consolidate the impact of multiple genetic variants, offering a comprehensive measure of genetic susceptibility. Individuals identified with elevated genetic risk scores may benefit from closer monitoring and targeted early intervention strategies to mitigate their predisposition [27].

Alongside genetic factors, traditional clinical risk factors including age, sex, hypertension, diabetes, smoking, and lipid levels remain fundamental in assessing CVD risk. Emerging biomarkers like high-sensitivity C-reactive protein (hs-CRP) and coronary artery calcium (CAC) score provide additional predictive value beyond conventional risk factors. Personalized risk prediction models integrate these diverse factors to refine risk stratification, enabling tailored interventions based on individualized risk profiles [28]. Furthermore, lifestyle factors play a pivotal role in cardiovascular health, encompassing dietary habits, physical activity levels, alcohol consumption, and stress management strategies. Incorporating these lifestyle variables into risk prediction models enhances predictive accuracy and empowers individuals to adopt healthier behaviors. Personalized lifestyle interventions, aligned with an individual's genetic predispositions, offer targeted preventive strategies. For instance, individuals genetically predisposed to impaired lipid metabolism may benefit from tailored dietary modifications and lipid-lowering medications, while those at risk for hypertension may prioritize lifestyle adjustments to mitigate their susceptibility [29].

Machine learning algorithms have revolutionized CVD risk prediction by leveraging extensive datasets comprising genetic, clinical, and lifestyle data. These sophisticated models uncover intricate interactions and identify novel risk predictors, thereby enhancing the precision of personalized risk assessment. Empowered with proactive measures, personalized risk prediction facilitates the implementation of targeted interventions including lifestyle modifications, pharmacological therapies, and behavioral counseling. Integration of genetic insights optimizes preventive strategies, identifying candidates for early screening and tailored interventions, ultimately improving health outcomes and optimizing healthcare resource allocation [30,31].

POTENTIAL OF PHARMACOGENOMICS AND TARGETED THERAPIES IN CARDIOVASCULAR DISEASE

In the realm of precision medicine, pharmacogenomics plays a pivotal role by deciphering how genetic variations influence individual responses to medications. By analyzing a patient's genetic makeup, healthcare providers can tailor pharmacotherapy and dosage regimens to optimize treatment outcomes while minimizing the risk of adverse reactions. This personalized approach is especially valuable in cardiovascular disease (CVD) management, where genetic insights help predict responses to medications like antiplatelet therapies and lipid-lowering agents, ensuring effective treatment strategies tailored to individual genetic profiles [32,33].



Figure 3 Potential of personalized medicine in treating various Heart conditions

Targeted therapies represent another cornerstone of precision medicine, focusing on specific molecular pathways implicated in CVD pathogenesis. Unlike conventional broad-spectrum treatments, targeted therapies aim at precise molecular targets, potentially enhancing treatment efficacy while reducing adverse effects. For instance, inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) have revolutionized the management of familial hypercholesterolemia by lowering LDL cholesterol levels significantly, thereby reducing cardiovascular risk [34,35].

Furthermore, the integration of pharmacogenomics and targeted therapies holds promise for mitigating cardiovascular risk by addressing underlying molecular mechanisms. Therapies targeting inflammatory pathways, such as interleukin-1 beta (IL-1β) inhibitors, show potential in reducing cardiovascular events by modulating inflammatory processes implicated in atherosclerosis progression and plaque stability. The application of these therapies, guided by genetic and molecular insights, represents a transformative approach to cardiovascular disease management, offering personalized treatment strategies tailored to individual genetic predispositions and disease characteristics [36,37].

CHALLENGES

Precision medicine holds immense promise for advancing cardiovascular disease (CVD) management but is challenged by several critical barriers. Data integration remains a central obstacle, requiring sophisticated frameworks to harmonize genomic, clinical, lifestyle, and environmental data effectively. Achieving interoperability across diverse data sources demands collaborative efforts among stakeholders to develop robust analytical tools capable of translating complex data into actionable insights for personalized care [38]. Ethical considerations also loom large in the implementation of precision medicine. The use of genetic data raises concerns about patient privacy, consent, and the potential for discrimination. Clear guidelines and stringent regulations are needed to safeguard patient autonomy, ensure informed consent, and prevent misuse of genetic information. Establishing robust governance frameworks and oversight mechanisms is crucial to uphold ethical standards and build trust in genomic-driven healthcare practices [39,40]. Addressing these challenges is pivotal to realizing the full potential of precision medicine in CVD management, fostering equitable access to innovative therapies while protecting patient rights and privacy.

FUTURE DIRECTIONS

Looking ahead, the future of cardiovascular disease (CVD) management through precision medicine is poised for significant advancements across multiple fronts. Genomics will continue to refine our understanding of genetic markers associated with CVD susceptibility and treatment response. This ongoing evolution enables healthcare providers to develop personalized treatment plans tailored to individual genetic profiles. By integrating genomic data into clinical decision-making, precision medicine holds the promise of optimizing therapeutic outcomes while minimizing adverse effects. This personalized approach has the potential to revolutionize how we approach and treat cardiovascular conditions, moving towards more effective and individualized care strategies.

Concurrently, ongoing research into novel biomarkers for CVD will enhance early detection, risk assessment, and monitoring of the disease. Biomarkers such as proteins, genetic markers, and metabolites offer insights into disease progression and treatment response, enabling clinicians to identify high-risk individuals and tailor interventions accordingly. Advances in biomarker discovery promise to refine diagnostic accuracy and prognostic capabilities, supporting targeted interventions that are better aligned with individual patient needs and disease characteristics.

Artificial intelligence (AI) and machine learning (ML) will play a crucial role in transforming cardiovascular care by improving risk prediction, diagnosis, and treatment optimization. AI algorithms can analyze large datasets encompassing genomic, clinical, and lifestyle information to uncover intricate patterns and correlations that may not be readily apparent to human practitioners. By harnessing AI-driven insights, healthcare providers can enhance diagnostic accuracy, predict individualized treatment responses, and optimize therapeutic strategies tailored to each patient's unique profile. Integrating AI and ML technologies into clinical practice has the potential to enhance decision-making, improve patient outcomes, and usher in a more personalized approach to managing cardiovascular diseases.

Looking forward, these advancements in genomics, biomarker discovery, and AI-driven technologies represent pivotal steps towards achieving precision medicine in cardiovascular care. By leveraging genetic insights, advancing biomarker research, and harnessing the power of AI, healthcare providers can deliver more precise, effective, and personalized care to patients with cardiovascular conditions. However, realizing the full potential of precision medicine will require continued investment in research, technological innovation, and collaborative efforts to ensure equitable access and implementation across diverse patient populations.

CONCLUSION

Precision medicine represents a promising frontier in cardiovascular disease management, leveraging genetic insights, omics technologies, and personalized risk prediction to optimize therapeutic strategies. Despite challenges in data integration and ethical considerations, ongoing advancements in genomics, biomarker discovery, and artificial intelligence hold immense potential to revolutionize patient care and improve cardiovascular outcomes globally. Embracing these innovations with collaborative efforts will be essential for realizing the full benefits of precision medicine in addressing the complex challenges of cardiovascular diseases.

Conflict of Interest: None.

Financial support: None.

Ethical statement: None.

REFERENCES

1. Sethi Y, Patel N, Kaka N, Kaiwan O, Kar J, Moinuddin A, et al. Precision Medicine and the future of Cardiovascular Diseases: A Clinically Oriented Comprehensive Review. J Clin Med. 2023;12(5):1799.
2. Safarlou CW, Jongsma KR, Vermeulen R, Bredenoord AL. The ethical aspects of exposome research: a systematic review. Exposome. 2023;3(1):1-41.
3. Coorey G, Figtree GA, Fletcher DF, Snelson VJ, Vernon ST, Winlaw D, et al. The health digital twin to tackle cardiovascular disease—a review of an emerging interdisciplinary field. npj Dig Med. 2022;5(1).
4. Liu Y, Du J. Precision Medicine in Cardiovascular Diseases. Cardiovasc Innov Appl. 2017;2(2):155.
5. Papadopoulou E, Bouzarelou D, Tsaousis G, Papathanasiou A, Vogiatzi G, Vlachopoulos C, et al. Application of next-generation sequencing in cardiology: current and future precision medicine implications. Front Cardiovasc Med. 2023;10:1202381.
6. Leopold JA, Loscalzo J. Emerging role of precision medicine in cardiovascular disease. Circ Res. 2018;122(9):1302-15.
7. Antman EM, Loscalzo J. Precision medicine in cardiology. Nat Rev Cardiol. 2016;13(10):591-602.
8. Gualandro DM, Twerenbold R, Boeddinghaus J, Nestelberger T, Puelacher C, Mueller C. Biomarkers in cardiovascular medicine: towards precision medicine. Swiss Med Wkly. 2019;149(4142):w20125.
9. Kathiresan S, Srivastava D. Genetics of human cardiovascular disease. Cell. 2012;148(6):1242-57.
10. Garg A, Fazio S, Duell PB, Baass A, Udata C, Joh T, et al. Molecular characterization of familial hypercholesterolemia in a North American cohort. J Endocr Soc. 2020;4(1):1-16.
11. Laggerbauer B, Engelhardt S. MicroRNAs as therapeutic targets in cardiovascular disease. J Clin Invest. 2022;132(11): e159179.
12. Shi Y, Zhang H, Huang S, Yin L, Wang F, Luo P, et al. Epigenetic regulation in cardiovascular disease: mechanisms and advances in clinical trials. Signal Transduct Target Ther. 2022;7(1):200.
13. Aragam KG, Jiang T, Goel A, Kanoni S, Wolford BN, Atri DS, et al. Discovery and systematic characterization of risk variants and genes for coronary artery disease in over a

million participants. Nat Genet. 2022;54(12):1803-15.
14. Shah SH, Newgard CB. Integrated metabolomics and genomics: systems approaches to biomarkers and mechanisms of cardiovascular disease. Circ Cardiovasc Genet. 2015;8(2):410-9.
15. Li H, Yang Y, Hong W, Huang M, Wu M, Zhao X. Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects. Signal Transduct Target Ther. 2020;5(1):1.
16. Fan Z, Peng W, Wang Z, Zhang L, Liu K. Identification of biomarkers associated with metabolic cardiovascular disease using mRNA-SNP-miRNA regulatory network analysis. BMC Cardiovasc Disord. 2021;21:1-2.
17. Lee Y, Yoon JW, Kim YA, Choi HJ, Yoon BW, Seo JH. A genome-wide association study of genetic variants of apolipoprotein A1 levels and their association with vitamin D in Korean cohorts. Genes. 2022;13(9):1553.
18. Doi T, Hori M, Harada-Shiba M, Kataoka Y, Onozuka D, Nishimura K, et al. and Miyamoto Y. Patients with LDLR and PCSK9 gene variants experienced higher incidence of cardiovascular outcomes in heterozygous familial hypercholesterolemia. J Am Heart Assoc. 2021;10(4): e018263.
19. Pelaia TM, Shojaei M, McLean AS. The Role of Transcriptomics in Redefining Critical Illness. Crit Care. 2023;27(1):1-7.
20. Miranda AM, Janbandhu V, Maatz H, Kanemaru K, Cranley J, Teichmann SA, et al. Single-cell transcriptomics for the assessment of cardiac disease. Nat Rev Cardiol. 2023;20(5):289-308.
21. Al-Amrani S, Al-Jabri Z, Al-Zaabi A, Alshekaili J, Al-Khabori M. Proteomics: Concepts and applications in human medicine. World J Biol Chem. 2021;12(5):57.
22. Lindsey ML, Mayr M, Gomes AV, Delles C, Arrell DK, Murphy AM, et al. Transformative Impact of Proteomics on Cardiovascular Health and Disease. Circulation. 2015;132(9):852–72.
23. Qiu S, Cai Y, Yao H, Lin C, Xie Y, Tang S, et al. Small molecule metabolites: discovery of biomarkers and therapeutic targets. Signal Transduct Target Ther. 2023;8(1):132.
24. Iliou A, Mikros E, Karaman I, Elliott F, Griffin JL, Tzoulaki I, et al. Metabolic phenotyping and cardiovascular disease: an overview of evidence from epidemiological settings. Heart. 2021;107(14):1123–9.
25. Zong D, Liu X, Li J, Ouyang R, Chen P. The role of cigarette smoke-induced epigenetic alterations in inflammation. Epigenetics & Chromatin. 2019;12:1-25.
26. Handy DE, Castro R, Loscalzo J. Epigenetic modifications: basic mechanisms and role in cardiovascular disease. Circulation. 2011;123(19):2145-56.
27. Ho WM, Wu YY, Chen YC. Genetic variants behind cardiovascular diseases and dementia. Genes. 2020;11(12):1514.
28. Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. J Lipids. 2015;2015:971453.
29. Rippe JM. Lifestyle Strategies for Risk Factor Reduction, Prevention, and Treatment of Cardiovascular Disease. Am J Lifestyle Med. 2018;13(2):204–12.
30. Ogunpola A, Saeed F, Basurra S, Albarrak AM, Qasem SN. Machine Learning-Based Predictive Models for Detection of Cardiovascular Diseases. Diagnostics. 2024;14(2):144.
31. Saikumar K, Rajesh V. A machine intelligence technique for predicting cardiovascular disease (CVD) using Radiology Dataset. Int J Syst Assur Eng Manag. 2024;15(1):135-51.
32. Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genomics Proteomics Bioinformatics. 2016;14(5):298-313.
33. Ventola CL. Role of pharmacogenomic biomarkers in predicting and improving drug response: part 1: the clinical significance of pharmacogenetic variants. Pharm Ther. 2013;38(9):545.
34. Martínez-Iglesias O, Naidoo V, Carrera I, Carril JC, Cacabelos N, Cacabelos R. Influence of metabolic, transporter, and pathogenic genes on pharmacogenetics and DNA methylation in neurological disorders. Biology. 2023;12(9):1156.
35. Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: a new era of lipid lowering therapy. World J Cardiol. 2017;9(2):76.
36. Jyotsna FN, Ahmed A, Kumar K, Kaur P, Chaudhary MH, Kumar S, et al. Exploring the complex connection between diabetes and cardiovascular disease: analyzing approaches to

mitigate cardiovascular risk in patients with diabetes. Cureus. 2023;15(8): e43882.

37. Marques L, Costa B, Pereira M, Silva A, Santos J, Saldanha L, Silva I, Magalhães P, Schmidt S, Vale N. Advancing Precision Medicine: A Review of Innovative In Silico Approaches for Drug Development, Clinical Pharmacology and Personalized Healthcare. Pharmaceutics. 2024;16(3):332.
38. Martínez-García M, Hernández-Lemus E. Data integration challenges for machine learning in precision medicine. Front Med. 2022;8:784455.
39. Stratton TP, Olson AW. Personalizing personalized medicine: the confluence of pharmacogenomics, a person's medication experience and ethics. Pharmacy. 2023;11(3):101.
40. Chakravarthy R, Stallings SC, Williams M, Hollister M, Davidson M, Canedo J, et al. Factors influencing precision medicine knowledge and attitudes. PLoS One. 2020;15(11):e0234833.